1

1 ENOX1, CCDC122 AND LACC1 ROLE IN PROGRESSION OF PROSTATE CANCER

2

- 3 Author list
- 4 Timothy Ongaba¹*
- ⁵ ¹School of Science and Technology
- 6 Nottingham Trent University
- 7 Clifton Campus
- 8 Clifton Lane
- 9 Nottingham
- 10 NG11 8NS
- 11 United Kingdom
- 12 Email: dextertim5@gmail.com
- 13

14 Abstract

Prostate cancer (PCa) continues to trend among top 3 cancers that kill men over 20 years in 15 the United Kingdom and worldwide despite extensive research and resources directed 16 towards its treatment and prevention. In the application of a hallmark of survival 17 mechanisms by the cancer, our study used mRNA seq data to identify genes that are 18 increasingly mutated with progressing PCa from a cohort of 491 PCa patients. We found 19 that ENOX1, CCDC122 and LACC1 deep deletion was positively associated with increasing 20 age of diagnosis. Pathway analysis of enriched genes, following their deep deletion 21 identified estrogen biosynthesis, KSRP signalling, omega 3 and 6 fatty acid biosynthesis 22 and, Rap1 signalling as the top 5 enriched pathways. Previous individual and combined role 23 of these genes in PCa progression was not fully established but thanks to this study, these 24 pathways could be druggable targets in PCa patients with these gene deep deletions. 25

26 Introduction

27 Background to the investigation

2

Prostate cancer (PCa) is the most frequently diagnosed cancer in men in 132 countries with a 28 7.3% incidence worldwide. It is the second cause of cancer deaths in men in 48 of 185 sampled 29 countries worldwide^{1,2}. One in 8 men will be diagnosed with prostate cancer in the UK while one 30 dies from the disease every 45 minutes. The number of PCa cases are projected to rise by 15% 31 in the UK between 2023 to 2025 indicating an ever-increasing trend ³. 32 33 PCa starts *in-situ* within the prostate where it can, but not always, metastasize to the lymph 34 nodes, bone, lung, liver and even as far as the brain when left untreated⁴. PCa can be termed 35 localised when it remains within the prostate or metastatic when it spreads beyond the prostate. 36 37 Localised PCa becomes high risk based on clinical staging, biochemical recurrence and a high Gleason score⁵. While still localised but more often when metastasised, PCa can progress from 38 hormone sensitive to refractory phenotype with increasing resistance to treatment and 39 decreasing survival rate from 30% over 5 to 30% over 3 years patient survival⁶. 40 When metastasised, the disease can be categorised as metastatic castration-sensitive prostate 41 cancer (mCSPC) when clinical deprivation of androgens halts cancer advancement. The disease 42 is termed castration-resistant prostate cancer(mCRPC) when cancer continues to progress even 43

in the absence of androgens. The risk of fatality significantly increases when PCa becomes

- 45 castration resistant⁵.
- 46

The incidence of PCa increases with age starting at 45, steeply rising and peaking around 75 to 79years. Patient survival is dependent on regular screening recommended to start at 45 years, early diagnosis and treatment intervention which might include chemotherapy, radiotherapy, surgical resection of tumours, immunotherapy or gland ablation to reduce the role of androgens in disease progression^{3,7,8}.

52

Tumour Mutational Burden (TMB) of PCa, the somatic cell rate of mutation per mega base pair has been associated with low response to chemotherapy, high biochemical recurrence and, generally poor prognosis. These together with other cofounders such as poor immune cell infiltration into the tumour microenvironment, and androgen receptor status quickly lead to reduced survival of affected individuals^{9–11}.

Among tumour mutations are gene deletions that can also appear as copy number alterations. Many of these, as deep deletions at chromosome 13q have been previously liked to poor prognosis in prostate cancer, high Gleason scores and biochemical recurrence¹²

61 Conversely, the high TMB also brings about high immunogenicity and, therefore, better response 62 to immunotherapy^{10,13}. This could, however apply to mutations in which the change in gene 63 sequence produces a more antigenic protein product detectable by the affected individual. A 64 deletion would lead to structural or functional alteration of the translated protein product.

65

Some of the most implicated genes in PCa are those involved in cell cycle progression, receptor
 signalling, proto-oncogenes, and or tumour suppressors. Among these, *UBE2C*, *PLK1*, *CDC20*,
 BUB1, *CDK1* and *HJURP* are top 6 linked to disease progression, metastasis and, poor
 prognosis^{9,10}.

3

70 Ecto-NOX Disulfide-Thiol Exchanger 1(ENOX1), also known as cCNOX, CNOX, FLJ10094, and 71 72 PIG38, is a copper-binding protein expressed in endothelial and other cells where it has NADH oxidase activity, promotes angiogenesis and is a potential druggable target ^{14–16}. It is one of the 73 74 genes on the 13q chromosome arm whose deletion is associated with poor prognosis, early biochemical recurrence and metastasis^{12,17} 75 ENOX1 has been negatively associated with prostate cancer, which is characterized by structural 76 rearrangements, most frequently including translocations between androgen-dependent genes 77 and other genes¹⁸. The Protein Atlas shows that *ENOX1* is expressed in cancer tissue, including 78 prostate cancer^{19,20}. ENOX1 shares a 66% sequence identity with ENOX2 of the same protein 79 family with demonstrated contribution to gastric cancer cell growth and survival²¹. The exact role 80 of ENOX1 in prostate cancer is, however, not fully understood, and further research is needed to 81 determine its functions and prognostic values¹⁶. 82 83

Coiled-Coil Domain Containing 122 (*CCDC122*) is a gene that is overexpressed in prostate cancer as compared to healthy prostate tissue^{22,23}. There is generally limited literature linking the gene or its products to prostate cancer and this warrants further studies following its differential expression and or mutation during the progression of disease. Single nucleotide polymorphisms in the gene have previously been linked to development of leprosy in case controlled cohorts of Chinese and Brazilian populations^{24,25}

90

91 The Laccase Domain-Containing 1(LACC1) gene is a gene that encodes an oxidoreductase that promotes fatty-acid oxidation, with concomitant inflammasome activation, mitochondrial and 92 NADPH-oxidase-dependent reactive oxygen species production, and anti-bacterial responses in 93 macrophages^{22,26-29}.In relation to prostate cancer, a transcriptome analysis of differentially 94 expressed genes in methotrexate-resistant prostate cancer found that LACC1 was one of the 95 genes that was differentially expressed³⁰. A study aimed at identifying biomarkers for the 96 management of human prostate cancer also found that LACC1 was one of the genes that was 97 differentially expressed in prostate cancer tissue compared to normal tissue³¹.Data from the TNM 98 99 plot shows a reduced expression of the gene in prostate cancer compared to normal prostate tissue²³. LACC1 has also been linked to Leprosy in similar studies as CCDC122^{24,25}. 100

101

102 Materials and Methods

103 Data retrieval from cbioportal

Using mRNA Seq data from the Prostate adenocarcinoma (TCGA Firehose Legacy) in cbioportal
 (<u>https://www.cbioportal.org/</u>), we examined quartiles of increasing age at time of diagnosis to
 identify what genes are incrementally altered with increasing age of diagnosis³².

107

108 Genomic alteration analysis of *ENOX1*, *CCDC122* and *LACC1*.

- 109 Of 491 samples/patients that had mRNA expression z-scores relative to all samples (log mRNA
- 110 Seq V2 RSEM) we used the onco query language "ENOX1: HOMDEL, CCDC122: HOMDEL,
- 111 LACC1: HOMDEL" as the user defined list, the mRNA expression z-score relative to all samples,
- in addition to putative copy number alteration from GISTIC and mutations were queried from the
- 113 study samples with mutation and Copy Number Alteration (CNA) data.

4

114 The z-score threshold was left at ±2.0 All other parameters were left as default.

- 115
- 116 Effect of ENOX1, CCDC122 and LACC1 in PCa
- 117 We examined mRNA seq data Z-score relative to all genes for patients that had deep deletions
- 118 for each of the three genes to compare their individual and combined effect on the survival of
- 119 PCa patients as overall survival.
- 120
- 121 Relationship analysis for ENOX1, CCDC122 and LACC1.
- 122 Using data from String database (available at <u>https://string-db.org/</u>) the three protein names
- were searched for under the "Multiple proteins" tab for "Homo sapiens" as the organism³³.
- 124

125 Pathway analysis using Enrichr and Reactome

126 To examine what genes are upregulated following the deep deletion of the three genes, we found

127 patient samples' mRNA expression (RNA Seq V2 RSEM) (491 samples) data that had at least

one deep deletion of *ENOX1*, *CCDC122* and *LACC1* (altered group of 81) and those with deep deletions of all three generative

129 deletions of all three genes(unaltered).

As our interest was pathway analysis of genes implicated with deep deletion of all 3 genes (*ENOX1*, *CCDC122* and *LACC1*), we selected for the "unaltered" gene category list with

132 statistically significant expression (95%CI) and ordered these by descending log2 ratio of the z-

- 132 score absolute values then by ascending p-value. All 432 genes were used an input for pathway
- analysis in Enrichr (<u>https://maayanlab.cloud/Enrichr/</u>)and later Reactome (<u>https://reactome.org/</u>)
- for cross reference ^{34,35}. The gene names were pasted in both analysis webpages and all parameters were left as default in the analysis tab.
- 137 Individual gene deep deletion effect on physiological pathways was not considered for analysis
- as patient data showed a multigene effect compounding disease status.
- 139
- 140 In Enricher, the most up-to-date manually curated pathway reference database and the highest
- 141 combined score for the top 4 pathways identified were chosen as the best reference database for
- 142 pathway analysis of the set of 432 genes.
- 143

144 Statistical analysis

- 145 All statistical analysis was done within cbioportal.
- 146
- 147
- 148 **Results**

149 Data retrieval /overview of Prostate Adenocarcinoma study (TCGA, Firehose Legacy).

150 To examine for genes increasingly mutated with progressing disease, we chose a cohort of PCa

151 patients with a wide range of age at time of diagnosis and Gleason primary and secondary

152 patters. Our chosen patient cohort with mRNA seq data for 498 patient samples suited well for

- 153 downstream analyses for PCa genomic analysis. (Figure 1).
- 154

Figure 1| Wide scope of age of diagnosis and Gleason scores. A shows age class boundaries of patients diagnosed with PCa. B represents different primary whereas C shows the secondary Gleason

157 patters making up different Gleason scores of PCa in patients.

5

- 158
- 159 Differential gene mutation with increasing age
- 160 Increasing age quartiles of PCa diagnosed patients showed differential genomic alterations.
- 161 Three of the genomically altered genes; *ENOX1*, *CCDC122* and *LACC1* had increasing gene
- deep deletions with increasing age at time of diagnosis with 0.0883, 0.146 and 0.146 p-values
- respectively. (Figure 2)
- All three genes were located on the 13q14.11 cytogenetic band having a deep deletion mutation.
- Figure 2| Genomically altered genes with increasing age quartiles *ENOX1*, *CCDC122* and *LACC1* are increasingly altered with increasing age of diagnosis.
- 168

169 Genomic alteration analysis of *ENOX1*, *CCDC122* and *LACC1*.

- 170 Sixteen percent (16%) of the 491 patient cohort had deep deletions of all three genes. All the
- three gene deep deletions had a co-occurrence tendency with p-values all less than 0.001 (95%
- 172 Cl) (Table1).
- 173

174 **Table 1** *ENOX1*, *CCDC122* and *LACC1* are concurrently deleted in in 491 patient samples

•	D	N I a ith a n	A Not	B Not	Dette	Log2 Odds	p-	q-	Tandanan
A	В	Neither	В	A	Both	Ratio	value	value	Tendency
ENOX1:	CCDC122:								
HOMDEL	HOMDEL	412	0	0	79	>3	<0.001	<0.001	Co-occurrence
CCDC122:	LACC1:								
HOMDEL	HOMDEL	410	2	0	79	>3	<0.001	<0.001	Co-occurrence
ENOX1:	LACC1:								
HOMDEL	HOMDEL	410	2	0	79	>3	<0.001	<0.001	Co-occurrence

175

- Analysis of any mutational data on the 3 genes irrespective of expression profile showed no patient had any mutation in the protein product of any of the (Supplementary figure 1)
- 178

179 Effect of ENOX1, CCDC122 and LACC1 deep deletion in PCa

180 There was no significant difference in overall survival between patient who had a deep deletion

- and those who had an amplification of all three genes on a Kaplan-Meier plot (Supplementaryfigure 2)
- 182 II 183
- 184 Relationship analysis for ENOX1, CCDC122 and LACC1.
- 185 CCDC122 and LACC1 proteins were found to be co-expressed with in addition to text mining 186 results. ENOX1, had no shown relationship with either gene (Figure 3).
- 187

Figure 3| *ENOX1* has not protein relationship with, *LACC1* and *CCDC122* which were liked with evidence of co-expression and text mining The three putative interactions were circled in red (*LACC1* and *CCDC122*) and black(*ENOX1*).

191

192 Pathway analysis using Enrichr and Reactome.

193 Reactome2022 was the database with the highest combined scores and most up-to-date in

194 Enrichr pathway analysis. The individual gene deep deletion implicated pathways were identical

195 between LACC1 and CCDC122 with ENOX1 having a more alike effect to the combined effect of

all three gene deep deletions.

197 The top 5 identified pathways ranking first by descending combined score then by ascending p-

value for all three genes' deep deletion were estrogen biosynthesis, KH-type splicing regulatory
 protein(KSRP), alpha linoleic and linolelic acid metabolism, and Rap1 signalling with
 114.62,110.08,82.59,67.35,56.94(2dp) combine scores respectively (Table 2).

201

Table 2| Top five upregulated genes were from estrogen biosynthesis, KSRP activity, omega 3 and, 6 and, Rap1 signalling pathway.

Index	Name/Pathway	P-value	Odds Ratio	Combined	Genes overlap
	Identifier			score	
1	Estrogen				
	Biosynthesis				AKR1B15;CYP19
	R-HSA-193144	0.006562	22.8030303	114.6185	A1
2	KSRP (KHSRP)				
	Binds and				
	Destabilizes				
	mRNA				DIS3;EXOSC8;PA
	R-HSA-450604	4.05E-04	14.09187534	110.0775	RN;YWHAZ
3	Alpha-Linolenic				
	(Omega3) And				
	Linoleic				
	(Omega6) Acid				
	Metabolism				ELOVL1;MUSK;S
	R-HSA-2046104	0.00242	13.70957944	82.58704	YCP2
4	Linoleic Acid (LA)				
	Metabolism				
	R-HSA-2046105	0.011904	15.2004662	67.3514	ELOVL1;MUSK
5	Rap1 Signalling				RAP1B;RAP1A;Y
	R-HSA-392517	0.004516	10.5442128	56.93941	WHAZ

204

Results from Reactome corroborated the same pathways as identified by Enrichr displaying genes that overlapped with those from known pathways (False Discovery Rate (FDR)<0.001). The top two of these with respective overlapping genes were highlighted (Figure 4). 184 genes were not mapped to any pathway by Reactome.

209

Figure 4| Gene's overlap (coloured yellow) between query genes mapped to known pathways by Reactome. Top is the estrogen biosynthesis pathway and bottom is the KSRP binding and destabilisation of mRNA pathway.

213

214 Discussion

Our study aimed to identify some of the most prevalent genomic alterations and or differentially expressed genes throughout the progression of disease. As age at diagnosis is often positively correlated and had previously been found to be linked with disease progression and poor prognosis, we examined quartiles of ages of patients diagnosed with prostate cancer to identify those genes whose alteration frequency was increasing with age and Gleason score(Figure1)^{36,37}.

7

Whereas the development and progression of prostate cancer is not pivotal on a single or only genomic mutations, we observed roles such as structural alterations and fusions attributed to TMPRSS2 gene and other chromosome 13q gene deletions among a hallmark of other factors PCa employs to develop, evade and progress in an individual. *ENOX1*, one of our identified genes is found on the same chromosome arm and we were able to identify its combined role with *CCDC122* and *LACC1* within the same cytogenetic band of 13q14.11 in progression of PCa as coexpression^{38,39}.

228

229 All the top 5 pathways implicated by upregulated genes following deep deletion of ENOX1, 230 LACC1 and, CCDC122 have been previously linked to cancer progression and give insight on 231 the beneficial effect of the three gene deletion to prostate cancer cell survival and disease 232 progression. The enriched pathways as a result of all three gene deletions were identical to those enriched by ENOX1 single gene deletion alone whereas single gene deletion of LACC1 and 233 234 CCDC122 had the same not identical effect to the pathways enriched by all three gene deletions (Supplementary figure 3). This suggests that the overall observed enriched pathways were more 235 as a result of single gene deletion of ENOX1 that either or both of LACC1 and CCDC122. 236

Estrogen has been shown to play a role in the development and progression of prostate cancer through its receptor activation on PCa cells that promotes cell proliferation and survival⁴⁰⁻⁴². Estrogen can stimulate the production of growth factors and cytokines that promote angiogenesis and tumour growth^{40,41,43}. Estrogen can inhibit the androgen receptor (AR) signalling pathway, and this is important for prostate cancer growth and survival^{40,43}.

242

243 KSRP (KH-type splicing regulatory protein) is an RNA-binding protein that has been shown to promote tumour growth and metastasis in non-small cell lung, breast, ovarian and, prostate 244 cancer⁴⁴. A study on castration-resistant prostate cancer showed that KSRP regulates type III 245 246 interferon expression post-transcriptionally, which is an important axis in the progression of prostate cancer especially in advanced stage⁴⁵. KSRP is also known to regulate gene expression 247 on various levels, including gene transcription, mRNA decay, and microRNA precursor 248 maturation⁴⁴. In colorectal cancer, enhanced expression of KSRP was found in tumour tissue and 249 250 was associated with worse overall survival. KSRP seemed to drive epithelial cell proliferation in primary and metastatic cells through control of cell cycle progression and promoted angiogenesis 251 by enhancing vascular endothelial growth factor⁴⁶. 252

253

254 Omega-3 and omega-6 fatty acids play a crucial role in the development and progression of prostate cancer. High amounts of omega-6 fatty acids have been linked with an increased risk of 255 prostate cancer, whereas omega-3 fatty acids have been shown to inhibit prostate cancer 256 257 growth⁴⁷. A study on athymic mouse xenograft model simulating radical prostatectomy showed 258 that prostate tumours can be modulated by the manipulation of omega-6:omega-3 ratios through diet, and the omega-3 fatty acid stearidonic acid (SDA) (precursor of eicosapentaenoic acid 259 (EPA)) can inhibit prostate tumour growth and recurrence⁴⁸. However, a study found that high 260 intake of omega-3 fats in the blood is linked to an increased risk of prostate cancer⁴⁹. Another 261 262 study showed that there were no significant associations between specific omega-3 or omega-6 PUFA intakes and overall prostate cancer risk⁵⁰. Our current findings show a beneficial role of 263 264 these two essential acids in PCa.

265

8

Ras-proximate-1 (Rap1) signalling has been shown to play a role in prostate cancer metastasis 266 and invasion⁵¹⁻⁵³. Specifically, Rap1 promotes tumour progression by disrupting E-cadherin-267 mediated cell adhesion, leading to a reduction in E-cadherin⁵⁴. Activation of Rap1 has also been 268 269 shown to increase prostate cancer cell migration and invasion through the $\alpha 4$, $\beta 3$, and $\alpha \nu \beta 3$ integrins⁵³. Additionally, a study found that miR-203 down-regulates Rap1A and subsequently 270 suppresses cell proliferation, adhesion, and invasion in prostate cancer⁵³. These studies 271 summatively suggest Rap1 contributes to PCa metastasis and, invasion in patients through 272 273 several pathways

274

Whereas our initial supposition was that *ENOX1*, *LACC1* and *CCDC122* were increasingly expressed to benefit PCa, our findings show that their deletion instead enriches genes that achieve the same outcome of PCa cell growth and survival.

- The novelty in our findings is the link between the three identified genes whose combined
- deletions enriches genes in in PCa cell benefiting pathways for disease cell growth and survival. The three gene protein products, however, have positive physiological body functions so it is
- putative that on deletion, redundant functionality from similar proteins whose deletion would be detrimental to PCa cells is employed as a substitute.
- 283

For a wet lab proof of concept, future work might involve use of PCa cell lines (RWPE-1, LNCaP, PC3, DU145) demonstrating different stage progression or stem cells of the disease and screening for the three genes using fluorescent *in-situ* hybridisation technique under the expectation of decreasing fluorescence with advancing disease.

As a therapeutic target for PCa and personalised therapy, judicial targeting of rate limiting steps/enzymes in the identified pathways could be explored as a treatment option should the side effect not outweigh the clinical benefit of the intervention.

291

292 Acknowledgments.

293 Special appreciation to Dr. Amanda Coutts (P.H.d) and the School of Science and Technology 294 for the guidance and resources used in executing this work.

295

296 **References**

- 2971.Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality298Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* **71**, 209–249 (2021).
- Chhikara, B. S. & Parang, K. Global Cancer Statistics 2022: the trends projection analysis. *Chem. Biol. Lett.* **10**, Vol. 10 No. 1 (2023) (2023).
- 3013.Prostatecancerincidencestatistics|CancerResearchUK.302https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-303type/prostate-cancer/incidence#heading-Three (2023).
- Hatzoglou, V. *et al.* Brain Metastases from Prostate Cancer: An 11-Year Analysis in the MRI Era
 with Emphasis on Imaging Characteristics, Incidence, and Prognosis. *J. Neuroimaging* 24, 166–
 166 (2014).
- Caster, J. M., Falchook, A. D., Hendrix, L. H. & Chen, R. C. Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on biopsy gleason score and PSA: A population-based study of modern patients. *Int. J. Radiat. Oncol. Biol. Phys.* (2015) doi:10.1016/j.ijrobp.2015.01.051.
- 311 6. Carroll, P. H. & Mohler, J. L. NCCN guidelines updates: Prostate cancer and prostate cancer

9

early detection. JNCCN J. Natl. Compr. Cancer Netw. 16, 620-623 (2018).

312

- 313 7. Held-Warmkessel, J. Treatment of advanced prostate cancer. Semin. Oncol. Nurs. 17, 118–128
 314 (2001).
- 8. Nanus, D. M. *et al.* Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. in *Journal of Urology* (2003). doi:10.1097/01.ju.0000095151.97404.7c.
- Luo, C., Chen, J. & Chen, L. Exploration of gene expression profiles and immune
 microenvironment between high and low tumor mutation burden groups in prostate cancer. *Int. Immunopharmacol.* 86, (2020).
- Wang, L., Pan, S., Zhu, B., Yu, Z. & Wang, W. Comprehensive analysis of tumour mutational
 burden and its clinical significance in prostate cancer. *BMC Urol.* 21, 1–10 (2021).
- 11. Lawlor, R. T. *et al.* Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: Systematic review and still-open questions. *Cancers (Basel).* **13**, (2021).
- 12. Kluth, M. *et al.* 13Q Deletion Is Linked To an Adverse Phenotype and Poor Prognosis in Prostate Cancer. *Genes Chromosom. Cancer* **57**, 504–512 (2018).
- 13. Chalmers, Z. R. *et al.* Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med.* **9**, (2017).
- Venkateswaran, A. *et al.* The NADH Oxidase ENOX1, a Critical Mediator of Endothelial Cell
 Radiosensitization, Is Crucial for Vascular Development. *Cancer Res.* 74, 38–43 (2014).
- Jiang, Z., Gorenstein, N. M., Morré, D. M. & James Morré, D. Molecular cloning and characterization of a candidate human growth-related and time-keeping constitutive cell surface hydroquinone (NADH) oxidase. *Biochemistry* 47, 14028–14038 (2008).
- Wu, Y. *et al.* Identification of the Functions and Prognostic Values of RNA Binding Proteins in
 Bladder Cancer. *Front. Genet.* **12**, 1–19 (2021).
- Science for Life laboratory, K. I. NM_001347969.2(ENOX1):c.759_765del (p.Ser254fs) AND
 Malignant tumor of prostate ClinVar NCBI. https://www.ncbi.nlm.nih.gov/clinvar/RCV000149057/
 (2023).
- Kluth, M. *et al.* Prevalence of chromosomal rearrangements involving non-ETS genes in prostate
 cancer. *Int. J. Oncol.* 46, 1637–1642 (2015).
- 340 19. Uhlen, M. *et al.* A pathology atlas of the human cancer transcriptome. *Science (80-.).* 357, (2017).
- 34220.Expression of ENOX1 in cancer Summary The Human Protein Atlas.343https://www.proteinatlas.org/ENSG00000120658-ENOX1/pathology (2023).
- Cheng, H. L., Lee, Y. H., Yuan, T. M., Chen, S. W. & Chueh, P. J. Update on a tumor-associated
 NADH oxidase in gastric cancer cell growth. *World J. Gastroenterol.* 22, 2900–2905 (2016).
- 346 22. Safran, M. *et al.* GeneCards[™] 2002: towards a complete, object-oriented, human gene 347 compendium. *Bioinformatics* **18**, 1542–1543 (2002).
- Bartha, Á., Gy, B. & Orffy, ["]. Molecular Sciences TNMplot.com: A Web Tool for the Comparison of
 Gene Expression in Normal, Tumor and Metastatic Tissues. (2021) doi:10.3390/ijms22052622.
- Xiong, J. H. *et al.* Association between genetic variants in NOD2, C13orf31, and CCDC122 genes
 and leprosy among the Chinese Yi population. *Int. J. Dermatol.* 55, 65–69 (2016).
- Leturiondo, A. L. *et al.* Association of NOD2 and IFNG single nucleotide polymorphisms with leprosy in the Amazon ethnic admixed population. *PLoS Negl. Trop. Dis.* **14**, 1–13 (2020).
- 35426.Fagerberg, L. et al. Analysis of the Human Tissue-specific Expression by Genome-wide355Integration of Transcriptomics and Antibody-based Proteomics* □ S. (2013)356doi:10.1074/mcp.M113.035600.
- 27. LACC1 Gene GeneCards | LACC1 Protein | LACC1 Antibody. https://www.genecards.org/cgi bin/carddisp.pl?gene=LACC1 (2023).
- Lahiri, A., Hedl, M., Yan, J. & Abraham, C. Human LACC1 increases innate receptor-induced
 responses and a LACC1 disease-risk variant modulates these outcomes. *Nat. Commun.* 8, (2017).
- Huang, C., Hedl, M., Ranjan, K. & Abraham, C. LACC1 Required for NOD2-Induced, ER Stress Mediated Innate Immune Outcomes in Human Macrophages and LACC1 Risk Variants Modulate
 These Outcomes. *Cell Rep.* 29, 4525 (2019).
- 364 30. Li, S. *et al.* Transcriptome analysis of differentially expressed genes and pathways associated 365 with mitoxantrone treatment prostate cancer. *J. Cell. Mol. Med.* **23**, 1987–2000 (2019).

10

- 366 31. Luca, B.-A. Identification of biomarkers for the management of human prostate cancer. (2017).
- 367 32. Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles using the 368 cBioPortal. *Sci. Signal.* **6**, (2013).
- 369 33. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage,
 supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 47,
 D607–D613 (2019).
- 372 34. Kuleshov, M. V *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016
 373 update. *Nucleic Acids Res.* 44, W90–W97 (2016).
- 374 35. Gillespie, M. et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, (2021).
- 375 36. Pettersson, A. *et al.* Age at diagnosis and prostate cancer treatment and prognosis: a population-376 based cohort study. *Ann. Oncol.* **29**, 377–385 (2018).
- 377 37. Cooney, M. M., Okuku, F. & Orem, J. Prostate Cancer Burden at the Uganda Cancer Institute. 2,
 378 181–185 (2019).
- 379 38. Perner, S. *et al.* TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with
 invasion. *Am. J. Surg. Pathol.* **31**, 882–888 (2007).
- 381 39. Braun, M. ERG rearrangement is specific to prostate cancer and does not occur in any other
 382 common tumor. (2012).

Bosland, M. C. SELECTIVE ESTROGEN RECEPTOR MODULATORS The Role of Estrogens in
 Prostate Carcinogenesis: A Rationale for Chemoprevention. *Rev. Urol.* 7, (2005).

- Ramírez-de-Arellano, A. *et al.* Distribution and Effects of Estrogen Receptors in Prostate Cancer:
 Associated Molecular Mechanisms. *Front. Endocrinol. (Lausanne).* 12, 811578 (2022).
- 42. Malaguarnera, R. *et al.* estrogens and Their Receptors in Prostate Cancer: Therapeutic implications. **8**, (2018).
- 389 43. Nelles, J. L., Hu, W.-Y. & Prins, G. S. Estrogen action and prostate cancer. (2011)
 doi:10.1586/eem.11.20.
- 44. Gherzi, R., Chen, C. Y., Trabucchi, M., Ramos, A. & Briata, P. The role of KSRP in mRNA decay
 and microRNA precursor maturation. *Wiley Interdiscip. Rev. RNA* 1, 230–239 (2010).

Schmidtke, L. *et al.* The KH-type splicing regulatory protein (KSRP) regulates type III interferon
 expression post-transcriptionally. *Biochem. J.* 476, 333–352 (2019).

- Palzer, K. A. *et al.* The Role of KH-Type Splicing Regulatory Protein (KSRP) for Immune
 Functions and Tumorigenesis. *Cells* 11, (2022).
- Apte, S. A., Cavazos, D. A., Whelan, K. A. & Degraffenried, L. A. A low dietary ratio of omega-6 to omega-3 Fatty acids may delay progression of prostate cancer. *Nutr. Cancer* 65, 556–562 (2013).
- 400
 48. Kelavkar, U. P. *et al.* Prostate tumor growth and recurrence can be modulated by the omega401
 6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy.
 402
 403
 404
 404
 405
 405
 406
 406
 406
 407
 407
 408
 408
 409
 409
 409
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
- 403 49. Brasky, T. M. *et al.* Plasma Phospholipid Fatty Acids and Prostate cancer risk in the Select trial.
 404 105, (2013).
- 405 50. Huerta-Yépez, S., Tirado-Rodriguez, A. B. & Hankinson, O. Role of diets rich in omega-3 and 406 omega-6 in the development of cancer. *Bol. Med. Hosp. Infant. Mex.* **73**, 446–456 (2016).
- 407 51. Zhang, Y. L., Wang, R. C., Cheng, K., Ring, B. Z. & Su, L. Roles of Rap1 signaling in tumor cell 408 migration and invasion. *Cancer Biol. Med.* **14**, 90–99 (2017).
- 409 52. Bailey, C. L., Kelly, P. & Casey, P. J. Activation of Rap1 Promotes Prostate Cancer Metastasis.
 410 *Cancer Res.* 69, 4962 (2009).
- 411 53. Jaśkiewicz, A., Pajką, B. & Orzechowski, A. The many faces of rap1 GTPase. *Int. J. Mol. Sci.* 19,
 412 1–20 (2018).
- 413 54. Looi, C. K., Hii, L. W., Ngai, S. C., Leong, C. O. & Mai, C. W. The Role of Ras-Associated Protein 414 1 (Rap1) in Cancer: Bad Actor or Good Player? *Biomedicines* **8**, (2020).









Regulation of mRNA stability by proteins that bind AU-rich elements:

